Shaping Convergent Strategies in Comparative Effectiveness Research

CER: Informing Public and Private Payer Decision-Making

June 24, 2010 Washington, DC

Charles Yarborough, MD, MPH, FACOEM, FACPM

1

Disclaimers

- I have not had significant direct funding with any pharmaceutical company for over 20 years.
- This presentation represents my personal views and not those of a current or past employer.
- The data is this presentation is either pro forma or in the published literature; there is no proprietary data.

CER Questions

- Do we need Comparative Effectiveness Research (CER) to improve plan members' health status?
- Will CER methods be selectively applied to companies' data sets?
- CER methods be important for assessing population impacts of alternative healthcare approaches? (an example)



*Dr. Dee Edington, Director, Health Management; Research Center, University of Michigan

Population Health as Strategic Component



Financial Management	Population Health Management
Stakeholder Engagement	Supplier Performance Management

Potential for Secondary Analyses of Existing Clinical Datasets for CER

Typical CER

- Estimating incidence and prevalence
- Estimating treatment needs
- Developing health policy
- Testing clinical hypotheses
- Performing meta-analyses
- Innovative challenges* (examples)
 - Cross-design synthesis to standardize and compare clinical data collected by different methods
 - Evaluation of new statistical models and methods on treatment effectiveness outcomes

*Ref.: NIH Challenge Grant 05-AA-101 (high priority)

NIH Challenge Grants for CER

- Prevention and Risk Factor Reduction Strategies for Disabilities (05-AG-102*)
- Comparative Effectiveness Studies of Non-Pharmacological Treatments for Chronic Low Back Pain (05-AT-101*)
- CER on Cancer Screening (05-CA-102*)
- Cost-Effectiveness of Patient Navigation (05-CA-103*)
- Understanding the Effects of Bariatric Surgery on Type 2 Diabetes and Cardiovascular Risk Factors (05-DK-101*)
- Support Pilot CER Projects in Community Settings (05-RR-102*)

Health of Individuals and Populations



Population Impact Assessments

- Ask the question -- make the options explicit
- Collect data
 - Relevant population denominators
 - Prevalence and current practice
 - Estimated data on baseline risk of identified outcomes
 - Library of evidence for risks (Relative Risks and Relative Risk Ratios)
- Calculate impact -- population impact measures
- Understand -- values, training, culture, receptivity
- Use -- implement results in prioritizing services using change and knowledge management

Population Impact Numbers

<u>Need</u>: Public health counterpart to evidence based medicine

<u>Solution</u>: Population impact measures to use evidence that is combined with collected data to provide local context to measure of risk and benefit, and to support health policy decision making

<u>Types</u>: Eliminating a risk factor (PIN-ER-*t*) and the number of events prevented by the intervention in your population" (NEPP)

Ref.: Heller RF, et al. 2003. Brit Med J 327.

Population Impact

* Includes embedded numbers

Total Population # Diseased* # Treated*

Events Prevented by Intervention*

Adapted from R. Heller "Evidence for Population Health" (2005), Oxford U. Press

Atorvastatin vs. Simvastatin Study*

- Case-referent design
- Full time employees from 23 companies with 2 years continuous postindex enrollment
- Matching (13,584 in each group)
 - Initial drug dose
 - Baseline inpatient CVD events
 - Average wage
 - Propensity score
- Primary study outcomes collected for 2 years
 - Rate of inpatient CVD events
 - Total costs to employers

*Simpson RJ, et al. 2009; Mayo Clin Proc 84(12):1065-1072 (authors funded by Pfizer) 13

Impact at 40% Prevalence by Rx Mix and Compliance



14

Impact at 20% Prevalence by Rx Mix and Compliance



Added Cost for Index Drug Depending on Prevalence and Rx Mix



Atorvastatin \$946 mean; Simvastatin \$489 mean.



- We need CER studies to enhance decision making for improving plan members' health status.
- CER methods can be selectively applied to and supplemented by companies' data sets.
- CER methods be important for assessing population impacts of alternative healthcare approaches.

Thank You